CHADS-65 (Canadian Society of Cardiology Guideline)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Oral Anticoagulation1–1
- Antiplatelet Therapy2–2
- No Antithrombotic Therapy3–3
The CHADS-65 (Canadian Society of Cardiology Guideline) calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include age 65 or older. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Clinical decision algorithm developed by the Canadian Cardiovascular Society to guide antithrombotic therapy for patients with nonvalvular atrial fibrillation or atrial flutter. Uses age-based approach to determine whether patients should receive oral anticoagulation, antiplatelet therapy, or no antithrombotic therapy for stroke prevention.
Clinical Indication
The CHADS-65 (Canadian Society of Cardiology Guideline) is indicated for bedside clinical practice to support Clinical decision algorithm developed by the Canadian Cardiovascular Society to guide antithrombotic therapy for patients with nonvalvular atrial fibrillation or atrial flutter. Uses age-based approach to determine whether patients should receive oral anticoagulation, antiplatelet therapy, or no antithrombotic therapy for stroke prevention.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.
Limitations & Contraindications
In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.
Clinical Pearls & Action Plan
Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines. Guideline pearl: ASA dose recommendation: 81mg daily for vascular disease patients.
Decision Algorithm: Step 1: Age ≥65? → OAC. Step 2: CHADS₂ risk factors present? → OAC. Step 3: Vascular disease present? → ASA. Otherwise → No therapy.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age_65_or_older | string | Yes | Patient age 65 years or older |
| congestive_heart_failure | string | Yes | History of congestive heart failure or left ventricular dysfunction |
| hypertension | string | Yes | History of hypertension or current antihypertensive treatment |
| diabetes_mellitus | string | Yes | History of diabetes mellitus or current antidiabetic treatment |
| stroke_tia_history | string | Yes | Previous stroke, transient ischemic attack, or thromboembolism |
| coronary_artery_disease | string | Yes | Coronary artery disease including myocardial infarction or coronary revascularization |
| peripheral_artery_disease | string | Yes | Peripheral artery disease including previous amputation, bypass surgery, or angioplasty |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | Oral Anticoagulation | Age ≥65 or CHADS₂ risk factors present |
| 2–2 | Antiplatelet Therapy | Age <65, no CHADS₂ risk factors, vascular disease present |
| 3–3 | No Antithrombotic Therapy | Age <65, no CHADS₂ risk factors, no vascular disease |
Evidence-Based References (EBM)
- Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020 Dec;36(12):1847-1948. doi: 10.1016/j.cjca.2020.09.001.DOI: 10.1016/j.cjca.2020.09.001
- Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014 Oct;30(10):1114-30. doi: 10.1016/j.cjca.2014.08.001.DOI: 10.1016/j.cjca.2014.08.001
- Canadian Agency for Drugs and Technologies in Health (CADTH). CHAD65 and CHA2DS2-VASc Risk Stratification Tools for Patients with Atrial Fibrillation: A Review of Clinical Effectiveness and Guidelines. Ottawa: CADTH; 2019 Mar.
- Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584.DOI: 10.1378/chest.09-1584